Literature DB >> 10227230

Interferon-beta 1b augments activation-induced T-cell death in multiple sclerosis patients.

A Kaser, F Deisenhammer, T Berger, H Tilg.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10227230     DOI: 10.1016/S0140-6736(99)00622-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.

Authors:  Kristina Ludigs; Valeriy Parfenov; Renaud A Du Pasquier; Greta Guarda
Journal:  Cell Mol Life Sci       Date:  2012-04-24       Impact factor: 9.261

2.  Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects.

Authors:  E M Martínez-Cáceres; M A Barrau; L Brieva; C Espejo; N Barberà; X Montalban
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

3.  Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients.

Authors:  M Ruggieri; C Avolio; S Scacco; C Pica; A Lia; G B Zimatore; S Papa; P Livrea; M Trojano
Journal:  J Neurol       Date:  2005-09-30       Impact factor: 4.849

4.  Interferon-alpha (IFN-alpha) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway.

Authors:  A Kaser; B Enrich; O Ludwiczek; W Vogel; H Tilg
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

5.  A Fashi Lymphoproliferative Phenotype Reveals Non-Apoptotic Fas Signaling in HTLV-1-Associated Neuroinflammation.

Authors:  Soraya Maria Menezes; Fabio E Leal; Tim Dierckx; Ricardo Khouri; Daniele Decanine; Gilvaneia Silva-Santos; Saul V Schnitman; Ramon Kruschewsky; Giovanni López; Carolina Alvarez; Michael Talledo; Eduardo Gotuzzo; Douglas F Nixon; Jurgen Vercauteren; David Brassat; Roland Liblau; Anne Mieke Vandamme; Bernardo Galvão-Castro; Johan Van Weyenbergh
Journal:  Front Immunol       Date:  2017-02-14       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.